In:
Tijdschrift voor Urologie, Springer Science and Business Media LLC, Vol. 10, No. 6-7 ( 2020-10), p. 147-154
Abstract:
Prostate-specific membrane antigen (PSMA) radioligand therapy is a novel treatment for castration-resistant prostate cancer (mCRPC). Currently, most data on PSMA radioligand therapy refer to 177 Lu-PSMA, a beta emitter. However, PSMA ligands can also be labelled to alpha emitting radionuclides, such as 225 Ac. Compared to beta emitters, alpha decay induces more harmful DNA damage. Thus, alpha emitter labelled PSMA ligands may have a better therapeutic effect compared to their beta emitting counterparts. Moreover, alpha decay has a much shorter linear energy transfer which could be beneficial in patients with micrometastases or diffuse bone-marrow infiltration. However, alfa-PSMA radioligand therapy is still experimental as there is only retrospective data available and prospective studies are awaited. Hence, the results require to be interpreted with caution. Also, production of 225 Ac and other alpha emitting isotopes needs to be increased significantly before clinical application. In this review, we summarize and discuss the current developments on alfa-PSMA radioligand therapy.
Type of Medium:
Online Resource
ISSN:
2211-3037
,
2211-4718
DOI:
10.1007/s13629-020-00301-y
Language:
Dutch
Publisher:
Springer Science and Business Media LLC
Publication Date:
2020
Permalink